MGNX(MacroGenics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $77.45M | $151.94M | $58.75M | $149.96M | $149.50M |
| 毛利润 | $74.80M | $148.59M | $58.13M | $149.12M | $149.50M |
| 营业利润 | −$202.79M | −$121.42M | −$168.24M | −$110.58M | −$72.84M |
| 净利润 | −$202.12M | −$119.76M | −$9.06M | −$66.97M | −$74.62M |
| 经营现金流 | −$143.83M | −$86.96M | −$78.20M | −$68.37M | −$81.04M |
| 自由现金流 | −$150.03M | −$90.58M | −$79.97M | −$72.08M | −$82.95M |
| 摊薄每股收益 | $-3.37 | $-1.95 | $-0.15 | $-1.07 | $-1.18 |